Anika Therapeutics Inc. (NASDAQ:ANIK) has been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Analysts have set a 1-year consensus price target of $52.00 for the company and are expecting that the company will post $0.44 EPS for the current quarter, according to Zacks. Zacks has also assigned Anika Therapeutics an industry rank of 123 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research downgraded Anika Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, May 8th.
In other news, Director Jeffery S. Thompson sold 10,725 shares of the firm’s stock in a transaction dated Monday, May 22nd. The stock was sold at an average price of $47.39, for a total transaction of $508,257.75. Following the completion of the sale, the director now directly owns 15,845 shares in the company, valued at $750,894.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Charles H. Sherwood sold 14,201 shares of the firm’s stock in a transaction dated Wednesday, July 5th. The shares were sold at an average price of $50.03, for a total value of $710,476.03. Following the sale, the chief executive officer now owns 246,740 shares of the company’s stock, valued at $12,344,402.20. The disclosure for this sale can be found here. 6.57% of the stock is owned by company insiders.
Several hedge funds have recently made changes to their positions in the stock. State Street Corp increased its stake in shares of Anika Therapeutics by 3.2% in the fourth quarter. State Street Corp now owns 316,791 shares of the biotechnology company’s stock valued at $15,507,000 after buying an additional 9,917 shares in the last quarter. Comerica Bank increased its stake in shares of Anika Therapeutics by 4.9% in the fourth quarter. Comerica Bank now owns 15,834 shares of the biotechnology company’s stock valued at $792,000 after buying an additional 739 shares in the last quarter. BB&T Securities LLC acquired a new stake in shares of Anika Therapeutics during the first quarter valued at $405,000. Fisher Asset Management LLC increased its stake in shares of Anika Therapeutics by 18.4% in the first quarter. Fisher Asset Management LLC now owns 70,153 shares of the biotechnology company’s stock valued at $3,047,000 after buying an additional 10,919 shares in the last quarter. Finally, Bbva Compass Bancshares Inc. acquired a new stake in shares of Anika Therapeutics during the first quarter valued at $355,000. Institutional investors own 80.80% of the company’s stock.
WARNING: “Analysts Expect Anika Therapeutics Inc. (NASDAQ:ANIK) to Announce $0.44 EPS” was originally reported by BNB Daily and is the sole property of of BNB Daily. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.baseball-news-blog.com/2017/08/19/analysts-expect-anika-therapeutics-inc-nasdaqanik-to-announce-0-44-eps-updated-updated-updated.html.
Shares of Anika Therapeutics (NASDAQ:ANIK) traded down 1.17% on Friday, hitting $47.35. The stock had a trading volume of 67,739 shares. The company has a market cap of $693.87 million, a price-to-earnings ratio of 22.85 and a beta of 1.68. Anika Therapeutics has a 12-month low of $41.38 and a 12-month high of $53.50. The stock has a 50 day moving average price of $47.54 and a 200-day moving average price of $46.90.
Anika Therapeutics (NASDAQ:ANIK) last announced its earnings results on Wednesday, May 3rd. The biotechnology company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.38 by $0.01. The business had revenue of $23.39 million for the quarter, compared to analyst estimates of $23.89 million. Anika Therapeutics had a net margin of 29.81% and a return on equity of 14.29%. The firm’s revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.45 earnings per share. On average, equities analysts expect that Anika Therapeutics will post $1.91 earnings per share for the current year.
About Anika Therapeutics
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.